Cancer Communications : Impact Factor & More
eISSN: 2523-3548pISSN: 2523-3548
Open AccessShare this on:
Key Metrics
CiteScore 
14.3
Impact Factor
15 - 20
SNIP
2.72
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cancer Communications
Cancer Communications Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Article-by-article |
| Article Processing Charges | USD 2500 |
| Publication Time | 4 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Chinese Anti-Cancer Association; US Chinese Anti-Cancer Association |
| Frequency | Article-by-article |
| Publication Start Year | 2018 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Cancer Communications ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cancer Communications
Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial
- 23 Jul 2026
- Cancer Communications
Decoding the Malignant Potential of Hydatidiform Moles through Fibroblast and LAIR2 Signatures
- 7 Jul 2026
- Cancer Communications
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences
- 17 Jun 2026
- Cancer Communications
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study
- 10 Jun 2026
- Cancer Communications
TGFBR1*6A and Risk for Colorectal Cancer
- 9 Jun 2026
- Cancer Communications
Impact of China\u2019s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs
- 4 Jun 2026
- Cancer Communications
Short-Course Radiotherapy-Based Total Neoadjuvant Therapy plus Tislelizumab for Locally Advanced Rectal Cancer (Neo-STAR): Early Outcomes of a Randomized Phase II Trial
- 23 Jul 2026
- Cancer Communications
Decoding the Malignant Potential of Hydatidiform Moles through Fibroblast and LAIR2 Signatures
- 7 Jul 2026
- Cancer Communications
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences
- 17 Jun 2026
- Cancer Communications
Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study
- 10 Jun 2026
- Cancer Communications
TGFBR1*6A and Risk for Colorectal Cancer
- 9 Jun 2026
- Cancer Communications
Impact of China\u2019s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs
- 4 Jun 2026
- Cancer Communications
FAQs on Cancer Communications
How long has Cancer Communications been actively publishing? 
What is the publishing frequency of Cancer Communications?
How many articles did Cancer Communications publish last year?
What is the eISSN & pISSN for Cancer Communications?
What is Citescore for Cancer Communications?
What is SNIP score for Cancer Communications?
Who is the publisher of Cancer Communications?
